COVID-19 mRNA Vaccines Preserve Immunogenicity after Re-Freezing

Santiago Grau*, Elena Martín-García, Olivia Ferrández, Raquel Martín, Sonia Tejedor-Vaquero, Ramón Gimeno, Giuliana Magri, Rafael Maldonado

*Autor corresponent d’aquest treball

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

4 Cites (Scopus)

Resum

The massive COVID-19 vaccine purchases made by high-income countries have resulted in important sample losses, mainly due to the complexity of their handling. Here, we evaluated the possibility of preserving the immunogenicity of COVID-19 mRNA vaccines after re-freezing vials, following the extraction of the maximum possible number of samples, as an alternative approach to minimizing their wastage. Thus, we exposed the vaccine vials to different re-freezing conditions and evaluated mRNA integrity and the effects in mice after in vivo administration. We reveal that the mRNA integrity of Comirnaty® and Spikevax® vaccines remained unaffected after re-freezing during 1 month at −20C or −80C. The immunological responses also remained unchanged in mice after these re-freezing conditions and no apparent side effects were revealed. The preservation of mRNA integrity and immunogenicity under these handling conditions opens the possibility of re-freezing the mRNA COVID-19 vaccine vials to limit their wastage and to facilitate vaccination processes.

Idioma originalAnglès
Número d’article594
RevistaVaccines
Volum10
Número4
DOIs
Estat de la publicacióPublicada - 12 d’abr. 2022

Fingerprint

Navegar pels temes de recerca de 'COVID-19 mRNA Vaccines Preserve Immunogenicity after Re-Freezing'. Junts formen un fingerprint únic.

Com citar-ho